Opinion|Videos|October 14, 2024
COSMOS-CRC-01: Clinicopathologic Correlation of ctDNA With RFS
Author(s)Yoshiaki Nakamura, MD, PhD
Yoshiaki Nakamura, MD, PhD, discusses how the COSMOS-CRC-01 study demonstrated statistically significant recurrence-free intervals across various postoperative and adjuvant chemotherapy time points, highlighting the prognostic value of serial, tissue-free ctDNA assays for real-time detection of MRD vs single postchemotherapy assessments.
Advertisement
Episodes in this series
1. Please summarize the statistically significant recurrence-free intervals across the postoperative, post-ACT, and paired pre- and post-ACT analyses in the COSMOS-CRC-01 study.
2. Please address the prognostic value of serial, tissue-free, epigenomic ctDNA assays in detecting MRD in real time vs a single postchemotherapy time point.
Newsletter
Stay up to date on practice-changing data in community practice.
SubscribeAdvertisement
Related to this article
During a live event, Seth M. Pollack, MD, and participants discussed 2 investigational agents for recurrent diffuse tenosynovial giant cell tumor and how dosing format, treatment duration, and reimbursement could shape the choice among targeted therapies.
A phase 2 trial is planned for an allogeneic CAR T-cell product in patients with lung or breast cancer with brain metastases.
RYZ101, a targeted alpha radiopharmaceutical, boosts progression-free survival in SSTR+ GEP-NETs after progression, offering a promising post-¹⁷⁷Lu option.
Natera’s blood test analyzes cell-free DNA to screen for several cancer types from a single sample.
A Japanese study found favorable sensitivity and specificity for recurrence of melanoma based on presence of melanoma-specific markers in circulating tumor DNA.
Theodore Wagener, PhD, of The Ohio State University discusses the design of the phase 2 DREAM LUNG study of psilocybin-assisted therapy for depression in non–small cell lung cancer.
"AI will not replace oncologists; it will help interpret complex data and design more precise, adaptive, personalized cancer treatment," the authors write.
The phase 2 NRG-BR002 failed to improve outcomes with targeted radiotherapy to oligometastases; the phase 3 portion will not proceed.
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Breakthrough Status to Multi-Cancer Early Detection Blood Test
2
FDA Clears Phase 2 Trial of B7-H3 CAR T MT027 for Brain Metastases
3
Alpha-Emitting RYZ101 Meets Phase 3 PFS End Point in Advanced GEP-NETs
4
Epigenomic ctDNA Assay Predicts Recurrence in Resected Melanoma
5